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ABSTRACT
Long non coding RNAs (lncRNAs) are defined as ncRNAs of more than 200 
nt in length. They are involved in a large spectrum of biological processes, such 
as maintenance of genome integrity, genomic imprinting, cell differentiation, and 
development by means of mechanisms that remain to be fully elucidated. Besides their 
role in normal cellular physiology, accumulating evidence has linked lncRNA expression 
and functions to cancer development and progression. In this review, we summarize 
and discuss what is known about their expression and roles in hematopoiesis with a 
particular focus on their cell-type specificity, functional interactions, and involvement 
in the pathobiology of hematological malignancies.
INTRODUCTION
In last years, after human genome sequencing, it 
became evident that although over 90% of the genome is 
actively transcribed [1, 2], the majority of transcripts is 
represented by non-coding RNA (ncRNA) and therefore 
not translated into canonical functional proteins. NcRNAs 
are represented by many classes, such as small interfering 
RNAs, microRNAs (miRNAs), PIWI-associated RNAs, 
small nucleolar RNA, and long ncRNAs (lncRNAs), 
including transcribed ultra-conserved regions (UCRs) and 
circular RNAs. NcRNAs are broadly divided into short 
(<200 nt) and long (>200 nt) transcripts. Dysregulation of 
short ncRNAs, particularly miRNAs, occurs in virtually 
all types of cancer, and this highlights the usefulness 
of miRNA profiling in diagnosis and prognosis, and in 
predicting response to therapy [3, 4]. Notably, they are 
currently considered both emerging therapeutic targets 
and innovative intervention tools in cancer, including 
hematological malignancies [5-7]. Among miRNAs with 
a relevant role in hematologic malignancies, we should 
mention miR-29 family members (miR-29a, miR-29b 
and miR-29c), reported to be widely dysregulated in 
hematologic cancers and demonstrated to target a number 
of epigenetic effectors, as reviewed by Amodio et al. [8].
LncRNAs are a heterogeneous group representing 
more than half of the mammalian non-coding 
transcriptome. They have an overall relative lower level of 
sequence conservation among mammalian species than the 
protein coding genes [9]. However, this finding does not 
directly imply lack of function, since most lncRNAs fold 
into complex secondary and tertiary structures important 
for their biological activity [10, 11]. Indeed, an improved 
algorithm identified more than four million of RNA 
secondary structures conserved in mammalian genomes, 
88% of which falling outside of known sequence-based 
conservation sites [12]. LncRNAs have been shown to be 
aberrantly expressed in cancer tissues and to be involved 
in oncogenic or tumor suppressive processes [13]. They 
are developmentally regulated and tissue-specific, and 
have been associated with a spectrum of biological 
processes, such as maintenance of genome integrity, 
X-chromosome inactivation, genomic imprinting, cell 
differentiation, and development. LncRNAs may also be 
defined based on their location relative to nearby protein-
coding genes. According to this, a lncRNA can be placed 
into one or more of five broad categories: (1) sense, or 
(2) antisense, when overlapping with one or more exons 
of another transcript on the same, or opposite strand, 
respectively; (3) bidirectional, when the sequence is 
located on the opposite strand from a protein coding gene 
whose transcription is initiated less than 1000 base pairs 
away; (4) intronic, when it is derived from within an intron 
of a different coding transcript in either sense or antisense 
orientation; or (5) intergenic (known as lincRNA), 
when it lies within the genomic interval between two 
coding genes at least 1kb away from the nearest coding 
gene [14-16] (Figure 1). The number of known human 
lncRNA transcripts is still evolving. LNCipedia v3.1 
contains some 111,685 human annotated lncRNAs, with 
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many loci generating multiple transcripts [17]. LncRNAs 
exhibit a structure and biogenesis that do not differ 
greatly from mRNAs. There are some lncRNAs that are 
transcribed by RNA polymerase III while the majority of 
lncRNAs are transcribed by RNA polymerase II, spliced 
and polyadenylated [18]. Compared to mRNAs, most 
lncRNAs localize preferentially to the nucleus, are more 
cell-type specific and are expressed at lower levels [2]. The 
mechanisms underlying the function of most lncRNAs are 
not fully understood. They may regulate gene transcription 
and translation through different mechanisms, such as 
interaction with RNA-binding proteins to reduce the 
translation activity of mRNA, protein complex recruitment 
to epigenetically regulate gene expression, or competition 
with mRNAs for miRNA binding [18-23] (Figures 2 and 
3). 
Dysregulation of distinct lncRNAs has been reported 
to promote tumor formation, progression, and metastasis 
in many types of cancer [24, 25]. Moreover, accumulating 
evidence suggests that lncRNAs have multiple functions 
in normal and malignant hematopoiesis [26-32], which 
can help to better understand the biology of hematopoiesis 
and blood diseases. In this review, we summarize what 
is known about lncRNAs in normal hematopoiesis and 
in hematological tumors. The data available thus far 
indicate that several lncRNAs may be key molecules in 
hematopoiesis and in the pathogenesis of hematological 
malignancies, and suggest the potential clinical relevance 
of lncRNAs in the diagnosis, prognosis, and therapy of 
these diseases.
Table 1: LncRNAs with roles in normal hematopoiesis
lncRNA Cell Type Function Reference(s)
EGO Eosinophils
Regulator of major basic protein (MBP) and eosinophil derived 
neurotoxin (EDN) mRNA expression during  eosinophil 
differentiation of CD34+ hematopoietic progenitor cells
[26]
PU.1-AS Monocytes; macrophages
Negative regulator of the hematopoiesis regulator PU.1 mRNA 
translation [35, 36]
HOTAIRM1 Myeloid progenitors
Regulator of the neighboring 3′ HOXA genes and other 
granulocytic differentiation genes [27, 37, 69]
lincRNA-EPS Erythroid progenitors
Anti-apoptotic activity on erythroid precursor, at least in part 
functionally related to the inhibited expression of the pro-apoptotic 
gene Pycard
[29]
lncRNA-EC7 Erythroid progenitors
Activator of the neighboring gene encoding BAND 3, the major 
anion transporter of the red cell membrane, probably acting as an 
enhancer RNA during erythrocyte maturation
[33]
NRON T cells
Regulator of dephosphorylation of the nuclear factor of activated 
T-cells 1 (NFAT1) transcription factor in the context of an RNA-
protein scaffold complex
[39]
Thy-ncR1 Thymic T cells
Regulator of T-cell selection and maturation, probably by indirectly 
controlling the degradation of MFAP4 (microfibril-associated 
glycoprotein 4) mRNA
[28]
TMEVPG1 T cells Regulator of T-cell differentiation implicated in the transcription regulation of the IFN-γ gene [41, 42]
linc-MAF-4 T cells Regulator of CD4
+ helper T-cell differentiation mediating the 
repression of MAF transcription in TH1 lymphocytes
[44]
BIC B cells Regulator of B-cell differentiation containing the mature miR-155 sequence [45-47, 49]
Figure 1: Categories of long non-coding RNA. Overview of five broad categories of lncRNAs (sense, antisense, bidirectional, 
intronic, intergenic; depicted in red) based on their location relative to nearby protein-coding genes (depicted in blue).
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LNCRNAS IN NORMAL HEMATOPOIESIS
Several lineage-specific lncRNAs have been already 
identified in the development of blood cells, although most 
of them have not yet been functionally characterized. 
Their physiological expression ensures the normal 
differentiation of hematopoietic stem cells and contributes 
to maintaining normal hematopoiesis (Figure 4, Table 1).
LncRNAs involved in erythroid differentiation
The first lncRNA to be related to red blood cells was 
the murine Erythroid ProSurvival lincRNA (lincRNA-
EPS), identified by RNA-sequencing as highly specific 
among approximately 400 lncRNAs with modulated 
expression during red blood cells differentiation [29]. 
Functional studies indicated that lincRNA-EPS is 
highly induced in erythroid precursors when they start 
synthesizing hemoglobin and other lineage-specific 
proteins. Knocking-down lincRNA-EPS in mouse 
inhibited differentiation and promoted apoptosis of 
erythroid precursors, while its ectopic expression could 
prevent this process. It has been suggested that the 
anti-apoptotic activity of lincRNA-EPS on erythroid 
progenitors might be at least in part functionally related to 
the inhibited expression of the pro-apoptotic gene Pycard 
through a still not defined mechanism [29].
In a recent high-throughput RNA-sequencing 
study of differentiating mouse fetal liver erythroid cells 
[33], Alvarez-Dominguez et al. identified more than a 
hundred not previously annotated lncRNA transcripts 
with erythroid-restricted expression. Many of them were 
targeted by key erythroid transcription factors, such as 
GATA1, TAL1, or KLF1, strongly supporting their roles 
during erythropoiesis. The deep investigation of twelve of 
these lncRNAs revealed that they were localized in the 
nucleus and exhibited complex patterns of expression 
during developmental stages. Their silencing severely 
impaired erythrocyte maturation by affecting cell-size 
reduction and subsequent enucleation. In particular, 
the lncRNA-EC7, transcribed from an erythroid-
specific enhancer, was required for the activation of the 
neighboring gene encoding BAND 3, the major anion 
transporter of the red cell membrane, probably acting as 
an enhancer RNA.
In a further study, Paralkar et al. used deep 
sequencing of polyadenylated RNAs to examine 
lncRNA expression in purified murine erythroblasts, 
megakaryocyte-erythroid precursors (MEPs), 
megakaryocytes, and in human erythroblasts [34]. 
Interestingly, they defined several lncRNAs unique to 
each cell type, demonstrating that most of them are 
transcribed from H3K4me3-rich gene promoters and 
are regulated by the same key transcription factors 
networks, including GATA1 and TAL1. Focusing on 
the erythroid lineage, they demonstrated that lncRNA 
expression was largely conserved among eight different 
mouse strains. In contrast, even though orthologous 
Figure 2: LncRNAs in epigenetic and transcriptional regulation. Four mechanisms of epigenetic and transcriptional regulation by 
lncRNAs are shown [18]. a. Direct interaction of lncRNAs with transcription factors (TFs) induces the allosteric change of the TFs towards 
activation. b. LncRNAs act as decoy for TFs by keeping them away from their targets on chromatin. c. LncRNAs act as a transcriptional 
guide by recruiting chromatin-modifying enzymes to target genes, either in cis or in trans to distant target genes. d. LncRNAs act as a 
scaffold, bringing together multiple proteins to form ribonucleoprotein complexes.
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regions were identified for about 90% of the lncRNA 
genes, only 15% of erythroid lncRNA genes expressed 
in mouse erythroblasts were also expressed in human 
erythroblasts at similar developmental and maturational 
stages, and vice versa. These findings reflect a marked 
species-specificity of lncRNAs. Furthermore, the 
Authors identified seven transcripts whose knockdown 
inhibited terminal maturation of primary mouse erythroid 
precursors. Of note, six of these seven lncRNAs had no 
detectable expression in human erythroblasts, even though 
orthologous genomic loci were identified. These findings 
suggest that the lack of expression of conserved lncRNA 
genes between mammalian species does not necessarily 
predict their biological inactivity. 
LncRNAs involved in myeloid differentiation
One of the first lncRNAs related to normal 
hematopoiesis to be identified was Eosinophil Granule 
Ontogeny (EGO), highly expressed in human bone 
marrow and in mature eosinophils [26]. This lncRNA 
was identified in eosinophil differentiation of CD34+ 
hematopoietic progenitor cells, where it regulates the 
mRNA expression of major basic protein (MBP) and 
Figure 3: LncRNAs in mRNA processing and post-transcriptional regulation. LncRNAs can act post-transcriptionally 
modulating mRNA processing at multiple levels [19]. a. Antisense lncRNAs associate with the sense mRNA, and the resultant RNA:RNA 
duplex might direct mRNA editing recruiting ADAR (adenosine deaminase acting on RNA) enzymes that catalyze adenosine to inosine 
conversion in double-stranded RNA. b. LncRNAs can prevent the alternative splicing of a pre-mRNA by binding the boundary site between 
its intron and exon. LncRNAs can also regulate RNA splicing by associating with splicing factors. c. LncRNAs may harbor the hairpin 
structure, which can give rise to the pre-miRNA. d. LncRNAs harboring the recognition site for functional miRNAs can function as miRNA 
decoys to sequester miRNAs from their mRNA targets. Furthermore, lncRNAs themselves can be the targets of miRNAs. e. LncRNAs can 
compete with miRNAs for binding on target mRNAs thus blocking miRNA-induced silencing through the RNA-induced silencing complex 
(RISC) and increasing mRNA translation. f. LncRNAs can regulate mRNA stability forming lncRNAs:mRNA double-stranded structures 
that can direct exosome mediated RNA degradation. For instance, Alu repeat-containing lncRNAs can associate with the Alu elements 
in the 3’ untranslated region (UTR) of an mRNA, and the resultant double-stranded structure can direct Staufen-mediated decay, thus 
destabilizing the target mRNA. g. LncRNAs association with the mRNA can positively or negatively modulate the translation efficiency, 
depending on the mRNA and lncRNA structures.
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eosinophil derived neurotoxin (EDN). EGO is transcribed 
antisense within an intron of the inositol triphosphate 
receptor type 1 (ITPR1) gene, and is conserved at the 
nucleotide level, with up to 90% identity among mouse, 
human, and chicken (http://genome.lbl.gov/vista) [26]. 
However, its mechanism of action has not been understood 
yet.
The lncRNA PU.1-AS is transcribed antisense to the 
transcription factor PU.1, with both sense and antisense 
transcripts originating from the same promoter. PU.1 is an 
essential regulator for normal hematopoiesis; its precise 
expression levels are crucial for specifying cell fate, and, 
if perturbed, can lead to leukemias and lymphomas [35]. 
Moreover, PU.1 plays a critical role in monocytes lineage 
commitment and monocyte/macrophage maturation 
[36]. PU.1-AS was demonstrated to negatively regulate 
PU.1 mRNA translation in murine and human cell lines 
by a mechanism similar to miRNAs, i.e. binding to 
PU.1 mRNA to form mRNA/AS lncRNA duplex, thus 
antagonizing the expression of PU.1 protein [35].
One of the best-studied lncRNAs involved in 
hematopoiesis is HOTAIRM1 (HOX antisense intergenic 
RNA myeloid 1), a lincRNA located between the human 
HOXA1 and HOXA2 genes. HOTAIRM1 is specifically 
expressed in the myeloid lineage, most highly in the 
terminal stage of granulocytic differentiation [27]. 
HOTAIRM1 was identified by microarray analysis as 
one of the lncRNAs induced during all-trans retinoid 
acid (ATRA)-driven granulocytic differentiation of the 
NB4 human acute promyelocytic leukemia cell line and 
normal myeloid lineage hematopoietic cells. Knockdown 
of HOTAIRM1 attenuated ATRA-induced expression 
of neighboring 3′ HOXA genes including HOXA1 and 
HOXA4, and selectively impaired the induction of 
transcripts for the myeloid differentiation markers CD11b 
(integrin alpha M chain), CD18 (integrin beta 2 chain) 
and CD11c (integrin alpha X chain), while retaining the 
expression of CD49d (integrin alpha 4 chain) [27, 37]. A 
resistance to ATRA-induced cell cycle arrest at the G1/S 
phase transition in knockdown cells was also observed 
[37], suggesting that the HOTAIRM1-modulated shift in 
CD49d and CD11c expression might function as a switch 
Figure 4: Involvement of lncRNAs in normal hematopoiesis. LncRNAs that regulate blood cell development are shown next to 
the cellular stage at which they act.
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regulating the transit from the proliferative phase to 
granulocytic maturation.
LncRNAs involved in lymphoid differentiation
The first genome-wide characterization of lncRNAs 
expressed in mammalian CD8+ T-cells [38] identified more 
than 1000 lncRNAs in human and mouse CD8+ T-cells, 
many of them displaying stage- or tissue-specificity. The 
expression of about 10% of these lncRNAs changed 
significantly during either CD8+ effector T-cells activation 
and/or naïve to memory cell differentiation. Furthermore, 
several of the lncRNAs neighbored protein-coding genes 
with well-characterized immunologically important roles 
in CD8+ T-cells, and/or overlapped shorter functional 
RNAs, suggesting that lncRNAs may be processed and 
exert their effects via smaller functional species.
Nuclear factor of activated T-cells (NFAT) proteins 
are Ca2+-regulated transcription factors controlling gene 
expression in many cell types. A study by Sharma et al. 
[39] in mouse CD8+ T-cells or HA-NFAT1 Jurkat T-cells, 
stably expressing HA (hemagglutinin)-tagged NFAT1-
GFP, provided evidence that a cytoplasmic complex 
involving the lincRNA NRON [noncoding (RNA) 
repressor of NFAT] and the IQ motif-containing GTPase-
activating protein 1 (IQGAP1) forms a scaffold for the 
inactive phosphorylated NFAT1 and its inhibitory kinases. 
Knockdown of linc-NRON in stimulated cells enhanced 
NFAT1 dephosphorylation and nuclear translocation, and 
increased production of NFAT-dependent cytokines. These 
data support the notion that lincRNAs may modulate gene 
expression by functioning as scaffolds for transcriptional 
regulators in the context of large RNA-protein complexes.
Another lncRNA related to T-cell differentiation, 
Thy-ncR1, is expressed specifically in the thymus, the site 
of T-lymphocyte maturation. Aoki et al. [28] identified 
Thy-ncR1 to be expressed only in a few human T-cell 
leukemia cell lines (DND41, HPB-ALL, Jurkat, and 
MOLT-3), all of which originated from immature stage III 
T-cells. The expression of the CD1 gene cluster, located 
118 kb from Thy-ncR1 gene, was highly correlated with 
Thy-ncR1 expression, implying a potential synergistic 
effect of CD antigens and lncRNAs during T-cell selection 
and maturation, although it is unclear if the expression 
of Thy-ncR1 is mechanistically linked to the CD1 gene 
cluster expression. In addition, the Authors suggested 
that Thy-ncR1 might participate in T-cell selection 
and maturation by an indirect control of the MFAP4 
(microfibril-associated glycoprotein 4) mRNA degradation 
[28]. MFAP4 encodes a protein containing a fibronectin-
like domain involved in cell adhesion. Although the role 
of MFAP4 in immature T-cells has not been defined yet, 
it was shown to support the ex vivo expansion of mouse 
hematopoietic stem cells [40].
TMEVPG1 and its murine ortholog are lincRNA 
genes located adjacent to the interferon (IFN)-γ-encoding 
gene in both mouse and human genome (IFNG). 
TMEVPG1 RNA is encoded antisense to IFN-γ. Initially 
identified in the context of Theiler’s virus infection in 
mice, the human ortholog TMEVPG1 is expressed in 
human NK cells and CD4+ and CD8+ T lymphocytes only 
when these subsets are not stimulated [41]. A study by 
Collier et al. [42] described TMEVPG1 and its murine 
ortholog as Th1-specific lincRNAs that require STAT4 and 
TBET transcription factors to drive the Th1 differentiation 
program, contributing to the transcription of the IFN-γ 
gene. Furthermore, in addition to increasing Theiler’s 
virus persistence in activated CD8+ T lymphocytes [43], 
murine Tmevpg1 was found to bind WDR5, a component 
of the H3K4 methyltransferase complex, and to alter H3 
methylation at the Ifn-γ locus. These findings suggest that 
lncRNAs may have a crucial role in T-cell differentiation 
and in susceptibility to infectious diseases acting as 
transcription regulators of pivotal cytokines.
A recent study by Ranzani et al. investigated 
lincRNAs in 13 highly purified human T and B 
lymphocytes subsets by RNA-sequencing and de novo 
transcriptome reconstruction [44]. They identified a 
lincRNA (linc-MAF-4) that seemed to have a key role 
in the differentiation of CD4+ helper T-cells. Indeed, 
the expression of this chromatin-associated lincRNA 
specific to the TH1 subset of helper T-cells was inversely 
correlated with expression of MAF, a TH2-associated 
transcription factor. Experimental downregulation of 
linc-MAF-4 skewed differentiating helper T-cells toward 
a TH2 transcription profile. The Authors suggested that 
linc-MAF-4 might regulate MAF transcription through 
the recruitment of the chromatin modifiers LSD1 and 
EZH2, exploiting a chromosome loop that brought its 
genomic region close to the MAF promoter. These results 
further demonstrate that lincRNAs can have a key role in 
T lymphocyte differentiation.
Among the few lncRNAs reported as acting in 
B-cell differentiation, it is worth to mention the B-cell 
integration cluster (BIC), even if a clear evidence of BIC 
acting as a “long” RNA has not been found yet [45, 46]. 
BIC consists of three exons spanning a 13 kb region at 
chromosome 21q21; it was found to be highly expressed 
in antigen receptor stimulated B- and T-cells as well as 
in macrophages and dendritic cells upon TLR (Toll-
like receptor) stimulation. Interestingly, the studies on 
this non-coding RNA have been mainly focused on its 
processed products, miR-155-5p and miR-155-3p, which 
play a key role in several biological processes, including 
hematopoiesis, inflammation and immune responses [47]. 
According to large-scale cloning studies [48], the BIC 
gene has now been designated as MIR155 host gene or 
MIR155HG (http://www.genenames.org/) whereas the BIC 
transcript is identified as pri-miR-155. Interestingly, high 
levels of BIC and miR-155 have been found in Hodgkin’s 
lymphoma, primary mediastinal B-cell lymphoma, 
diffuse large B-cell lymphoma, chronic lymphocytic 
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leukemia (CLL), AML and some solid tumors, but they 
are not expressed in healthy samples [47], indicating 
that this locus may be linked to cancer. Concerning miR-
155, we should note that it has been reported by Calin et 
al. [49] to target other types of non coding RNA, such 
as genomic transcribed UCRs. Interestingly, Petri et al. 
[50] have recently analyzed lncRNA expression during 
human B-cell development by array-based expression 
profiling of eleven distinct B-cell subsets isolated by 
flow cytometry cell-sorting from human tonsils and bone 
marrow. By means of a weighted gene co-expression 
network analysis, they identified several lncRNAs within 
well-defined gene networks involved in specific stages of 
B-cell development, such as early B-cell development, 
B-cell proliferation, affinity maturation of antibody, 
and terminal differentiation. These findings may be 
an important resource for future studies exploring the 
functions of lncRNAs in normal B-cell lymphopoiesis. 
Moreover, they might provide the basis for understanding 
the roles of lncRNAs in the pathogenesis and progression 
of B-cell malignancies that originate from distinct B-cell 
subpopulations.
LNCRNAS DYSREGULATED IN 
HEMATOLOGICAL MALIGNANCIES
The central role of lncRNAs in regulating blood 
cell fates, including differentiation, proliferation and 
survival, suggests that they might be involved in the 
pathogenesis of hematopoietic malignancies. Whatever 
the mechanism(s) through which lncRNAs execute their 
functions, they may contribute to disease by misregulating 
target genes or signaling pathways crucial for disease 
onset and progression. Thus far, only few lncRNAs have 
Table 2: Overview of the most frequently deregulated lncRNAs in hematological malignancies
lncRNA Hematologicdisease Function
Molecular 
mechanism Reference(s)
XIST MPN, MDS Tumor suppressor Not described [32, 51]
H19 
CML, PV, ET, PMF, CMML, 
AML, adult T-cell leukemia/
lymphoma
Oncogene/tumor 
suppressor
Activated by c-Myc.
Precursor of miR-675 targeting 
RB
[52-58]
BGL3 CML Tumor suppressor
Competitive endogenous RNA 
cross-regulating the expression of 
the tumor suppressor PTEN
[59]
IRAIN AML Tumor suppressor
Interaction with the promoter and 
enhancer regions of the IGF1R 
gene
[60, 61]
MEG3 AML; MDS; MM Tumor suppressor
Regulation of the Rb-p16INK4a 
pathway.
P53 activation
[62-67]
LUNAR1 T-ALL Oncogene
NOTCH1-regulated. 
Activation of IGF1R expression in 
cis by recruitment of the Mediator 
complex and RNA polymerase II 
to the IGF1R enhancer
[72]
DLEU2 CLL, MCL, MM Tumor suppressor
NF-kB activation. 
Host of miR-15a/16-1 cluster 
targeting BCL2
[76, 78-85, 115]
ANRIL ALL, AML Oncogene
PRC1 and PRC2 recruitment to 
epigenetically silence INK4b-
ARF-INK4a tumor suppressor 
locus
[31, 86-89]
GAS5 B-cell lymphoma, T-cell leukemia Tumor suppressor
Glucocorticoid receptors 
antagonist. 
Regulated by mTOR pathway
[85, 90-101]
TUG1 MM, CLL Oncogene
PRC2 binding to repress cell-
cycle regulation genes.
Induced by p53
[101, 102]
MALAT1 MM Oncogene
Sp1 recruitment to the promoter 
of LTBP3 gene regulating the 
bioavailability of TGF-β
[25, 85, 108-114, 
116, 117]
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; 
CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; ET, essential thrombocythemia; MCL, mantle 
cell lymphoma; MDS, myelodysplastic syndrome; MM multiple myeloma; MPN, myeloproliferative neoplasm; PMF, primary 
myelofibrosis; PV, polycythemia vera
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been conclusively linked to the initiation and progression 
of hematological malignancies, though the list is expected 
to grow exponentially in the near future (Table 2).
LncRNAs in myeloproliferative diseases
X-inactive-specific-transcript (XIST), one of the 
several lncRNAs located on the X chromosome and 
participating in the X chromosome inactivation during 
embryogenesis, has long been associated with human 
cancer [51], but only recently it has been causally 
linked to the development of hematologic tumors in 
mouse models [32]. In fact, by deleting Xist in vivo in 
murine hematopoietic stem cells after the occurrence 
of X inactivation, Yildrim et al. were able to induce 
highly aggressive lethal myeloproliferative neoplasm 
and myelodysplastic syndrome (MPN/MDS), with 
100% penetrance, in both the female homozygous 
and heterozygous conditions, whereas male mutants 
remained healthy and viable throughout the 2-year 
observation period [32]. These results suggested that Xist, 
in addition to be directly involved in the formation of 
repressive chromatin for dosage compensation, has also 
an important role in tumor suppression in vivo. Indeed, 
Xist loss resulted in X reactivation and the induction of 
genome-wide changes associated with cancer, including 
dysregulation of oncogenes or tumor suppressor genes 
involved in MPN and MDS [32].
H19 was the first imprinted lncRNA gene identified. 
Genomic imprinting is a form of epigenetic gene regulation 
that results in expression of a single allele in a parent-of-
origin-dependent manner. H19, abundantly expressed 
during embryonic development and downregulated after 
birth, is transcribed from the H19/insulin-like growth 
factor 2 (IGF2) cluster: H19 is expressed from the 
maternal allele and IGF2 from the paternal allele [52]. 
Dysregulation of lncRNA H19 has been observed in 
various tumors, and it was described acting either as an 
oncogene or a tumor suppressor [52]. Reduced expression 
of H19 was observed in clinically untreated chronic 
myeloproliferative disorders, including chronic myeloid 
leukemia (CML), polycythemia vera (PV), essential 
thrombocythemia (ET), primary myelofibrosis (PMF) 
and chronic myelomonocytic leukemia (CMML), as well 
as in AML [53, 54]. Interestingly, a critical requirement 
for H19 was recently demonstrated in Bcr-Abl-mediated 
tumorigenesis [55]. This lncRNA was found upregulated 
in human K562 Bcr-Abl-positive leukemia cell line and 
primary CMLs in a Bcr-Abl kinase-dependent manner. 
Downregulation of H19 expression in K562 cells affected 
cell survival and attenuated tumor formation in xenograft 
mouse model suggesting a functional involvement 
of H19 in Bcr-Abl-mediated cellular transformation. 
Noteworthy, loss of imprinting of H19, resulting in high 
H19 expression, was described in adult T-cell leukemia/
lymphoma patients and cell lines [56], suggesting that 
H19 might play different roles in distinct hematological 
tumors. The fact that H19 is also the precursor of miR-
675 [57], known to downregulate the retinoblastoma (RB) 
gene in human colorectal cancer [58], adds a further level 
of complexity to the functional roles that H19 may have in 
different signaling pathways and cell contexts.
Another lncRNA acting as a key regulator of Bcr-
Abl-mediated cellular transformation is the Beta Globin 
Locus 3 (BGL3) [59]. This lncRNA was upregulated by 
disruption of Bcr-Abl expression or inactivation of Abl 
kinase after exposure to imatinib in K562 cell line and 
primary CML samples. It was also observed that the 
ectopic expression of BGL3 sensitized K562 leukemic 
cells to imatinib-induced apoptosis and inhibited Bcr-
Abl-induced tumorigenesis in xenograft mouse model. 
Furthermore, transgenic mice expressing BGL3 exhibited 
impaired Bcr-Abl-mediated primary bone marrow 
transformation. These observations suggest that BGL3 
might act as a tumor suppressor during Bcr-Abl-induced 
tumorigenesis. The Authors also demonstrated that 
BGL3 was a target of a set of miRNAs known to repress 
the tumor suppressor phosphatase and tensin homolog 
(PTEN) gene, then suggesting that BGL3 might function 
as a competitive endogenous RNA to cross-regulate PTEN 
expression [59].
IRAIN is a recently discovered imprinted lncRNA, 
expressed exclusively from the paternal allele within 
the insulin-like growth factor type I receptor (IGF1R) 
locus [60]. IRAIN is transcribed antisense to IGF1R 
and is involved in the formation and/or maintenance of 
a long-range intrachromosomal loop between the IGF1R 
promoter and a distant intragenic enhancer. IGF1R is 
known to play a critical role in AML, promoting cell 
growth in samples with an activated phosphoinositide 3 
kinase (PI3K)/Akt signaling pathway [61]. Interestingly, 
IRAIN was found downregulated in leukemia cell lines 
and in patients with high-risk AML [60]. This observation 
suggests that IRAIN downregulation might relax the 
‘transcription competition’ control, which may contribute 
to activate the IGF1R gene, leading to growth advantage 
and tumor progression.
The maternally expressed gene 3 (MEG3) is a 
lncRNA with a tumor suppression function mediated by 
both p53-dependent and p53-independent mechanisms 
[62]. The expression of the MEG3 gene is under epigenetic 
control, and aberrant CpG methylation has been observed 
in several types of cancer. Indeed, MEG3 is commonly 
downregulated in many types of tumors including 
hematological malignancies such as AML, MDS or 
multiple myeloma (MM) and the hypermethylation of its 
promoter is a marker of poor prognosis [63-65]. Although 
no clear role in the etiology of AML has emerged for 
MEG3, it is likely that it may contribute to the disease via 
its known effects on cell proliferation through regulation 
of the RB and p16INK4a pathway [66, 67].
Recently, Garzon et al. [68] investigated the 
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associations of lncRNA expression with clinical features, 
recurrent mutations, and outcome in cytogenetically 
normal AML (CN-AML) patients. They identified 
distinctive lncRNA profiles associated with the most 
common recurrent mutations in CN-AML, such as FLT3-
ITD and those affecting NPM1, CEBP, IDH2, and RUNX1 
genes. Interestingly, a lncRNA score was derived, which 
strongly correlated with treatment response and survival 
[68]. Patients with NPM1 mutations showed one of the 
strongest lncRNA signatures with many up-regulated 
lncRNAs transcribed antisense to HOX genes, such 
as HOXB-AS3 and MEIS1-AS2. As discussed above, 
HOTAIRM1, a lncRNA transcribed antisense to the HOXA 
genes, has been suggested to play a role in myelopoiesis 
[27, 37]. Notably, HOTAIRM1 was also found upregulated 
in a large series of AML patients with intermediate-
risk cytogenetics, in particular in patients with NPM1 
mutation, showing an independent negative prognostic 
value [69]. These findings suggest a role of HOX genes in 
the context of AML with NPM1 mutations.
LncRNAs in lymphoproliferative diseases
NOTCH1 receptor signaling is known to play 
a central role in T-cell lineage commitment and in 
supporting the growth and proliferation of immature T-cell 
progenitors during lymphoid development in the thymus 
[70]. Human T-cell acute lymphoblastic leukemia (T-ALL) 
is generally associated with NOTCH1 gene mutations that 
trigger an aberrant and constitutively active NOTCH1 
signaling [71]. Recently, Trimarchi et al. [72] have shown 
that a specific NOTCH1-regulated lncRNA, LUNAR1 
(LeUkemia-induced Non-coding Activator RNA-1), is 
upregulated in NOTCH1 mutated T-ALL and is essential 
for efficient T-ALL growth in vitro and in vivo due to its 
ability to enhance the expression of its neighboring coding 
gene on chromosome 15, IGF1R, thus sustaining the IGF1 
signaling. IGFR1 receptor has been previously suggested 
to mediate important growth/survival signals in T-ALL 
[73]. Through a chromatin loop, that places the IGF1R 
enhancer and the LUNAR1 promoter in close proximity, 
the intronic IGF1R enhancer activates the transcription of 
LUNAR1, which in turn co-occupies this enhancer and 
sustains the IGF1R expression and signaling [72].
Deleted in leukemia 1 (DLEU1) and 2 (DLEU2) 
are two lncRNAs whose genes map in critical region at 
chromosome 13q14.3 found to be deleted in more than 
50% of CLL patients [74, 75]. DLEU2 gene hosts miRNAs 
15a and 16-1, a cluster having a crucial role in the 
pathogenesis of CLL, in part by regulating the expression 
of the oncogene B cell lymphoma 2 (BCL2) [76, 77]. Mir-
15a and mir-16-1 precursors are localized in intron 4 of 
DLEU2 gene, on the same chromosome strand. In a recent 
study, mice deleted for the entire minimal deleted region 
(MDR) within 13q14, comprising the DLEU2 lncRNA 
gene, developed clonal B-cell proliferations recapitulating 
the spectrum of CLL-associated phenotypes observed in 
humans, and displayed a significantly more aggressive 
phenotype than miR-15a/16-1-deleted mice [78]. Another 
study showed that DLEU2 had a potent inhibitory effect 
on cellular proliferation and colony-forming ability of 
tumor cell lines in a miR-15a/16-1-dependent manner 
[79]. Furthermore, DLEU2 expression caused a clear 
downregulation of the Cyclin D1 and Cyclin E1 protein 
levels in a way dependent on the expression of miR-
15a/16-1. Taken together, these findings have suggested 
that loss of DLEU2 might contribute to CLL through 
the absence or functional loss of miR15a/16-1, although 
additional, yet unexplained, roles for DLEU2 in CLL 
development might be hypothesized. Furthermore, DLEU1 
and DLEU2 were found to be significantly demethylated 
at the 5’ ends in almost all of CLL patients characterized 
by Garding et al. [80]. Demethylation correlated with 
transcriptional deregulation of a cluster of neighboring 
protein-coding tumor suppressor genes, which may act 
as positive regulators of NF-kB activity. As no significant 
enrichment of DLEU1 or DLEU2 transcripts was found 
at chromatin level, the Authors suggested that the two 
lncRNAs regulate the neighboring cluster genes by 
divergent transcription. Interestingly, deletion of the 
chromosome 13q14 region is a common genetic aberration 
in other types of lymphoid malignancies, such as mantle 
cell lymphoma (MCL) [81, 82] and, in particular, 
MM [83, 84]. This may suggest a role for DLEU2 also 
in the development of these hematological diseases. 
A recent study by Ronchetti et al. [85] investigated 
lncRNA expression profiles in a large cohort of samples 
representing all the major different forms of plasma cell 
(PC) dyscrasias, including monoclonal gammopathy of 
undetermined significance (MGUS), smoldering MM 
(SMM), truly overt and symptomatic MM, and extra-
medullary myeloma/plasma cell leukemia (PCL) patients. 
The Authors found a significant downregulation of 
DLEU2 in patients carrying del13; in addition, DLEU2 
expression significantly correlated with that of miR-15a 
and miR-16-1.
ANRIL (Antisense Non-coding RNA in the INK4 
Locus) is a cell cycle-related lncRNA transcribed antisense 
to the INK4b-ARF-INK4a locus, which encodes three 
crucial cyclin-dependent kinase inhibitors, p15INK4b, p14ARF 
and p16INK4a [86]. These inhibitors undergo epigenetic 
silencing in hematopoietic stem cells and play central roles 
in cell cycle inhibition, senescence, differentiation, and 
stress-induced apoptosis [87]. ANRIL is a key regulatory 
molecule mediating human disease at different levels and 
cellular settings. A statistically significant association 
between an ANRIL polymorphism and Philadelphia 
positive ALL (Ph+ ALL) was observed [88]. Furthermore, 
an inverse correlation between ANRIL and p15 expression 
was discovered in patients with ALL and AML [31], 
suggesting an ANRIL-dependent regulation mechanism 
for p15 in leukemia. Indeed, a cis-regulation of the INK4 
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locus by ANRIL leading to the subsequent silencing of 
this gene locus by H3K27-trimethylation, as observed 
in prostate cancer tissues [89], might be suggested in 
leukemogenesis. In fact, ANRIL could be involved in cis 
recruitment of Polycomb Repressive Complex 1 (PRC1) 
and 2 (PRC2) for the epigenetic silencing of p14, p15, and 
p16, with subsequent induction of cell cycle perturbations, 
differentiation block, and apoptosis arrest in blood cells, 
leading to leukemia.
Growth Arrest Specific 5 (GAS5) is a cell-
cycle arrest and apoptosis-related lncRNA with tumor 
suppressor activity [90-94]. Interaction of GAS5 with the 
DNA binding domain of glucocorticoid receptors (GRs) 
leads to the suppression of glucocorticoid-mediated 
transcription of several antiapoptotic genes in HeLa cells 
[95]. GAS5 is encoded at 1q25.1 locus that has been 
associated with diffuse large B-cell lymphoma [92, 96] 
as a result of recurrent breakpoints or duplication events. 
GAS5 transcript levels were found significantly reduced 
in breast cancer [91], renal cell carcinoma [93], non-
small-cell lung carcinoma [94], hepatocellular carcinoma 
[97], and cervical cancer tissues [98]. Interestingly, GAS5 
has also been shown to be regulated by the mammalian 
target of rapamycin (mTOR) pathway and to mediate the 
effect of mTOR antagonists, such as rapamycin, on the 
cell cycle in T-cells [99]. Indeed, downregulation of GAS5 
using RNA interference protected both leukemic and 
primary human T-cells from the inhibition of proliferation 
produced by mTOR antagonists [100]. In their recent 
work, Ronchetti et al. [85] found GAS5 progressively 
dysregulated from normal to pathological PCs through 
the increasingly aggressive stages of PC dyscrasia. 
Additionally, GAS5 was specifically upregulated in 
samples with 1q gain lesion. In contrast with the evidence 
of GAS5 overexpression in MM cells [85], a study by 
Isin et al. investigating the circulating levels of selected 
lncRNAs in plasma of patients with B-cell malignancies 
found that expression of GAS5 was significantly lower in 
the patients with MM compared to the levels in healthy 
subjects [101]. However, more studies are needed to fully 
elucidate these findings.
Another lncRNA deregulated in cancer is the taurine 
upregulated gene 1 (TUG1). Its expression levels were 
found significantly different in plasma of patients with 
MM compared to healthy subjects [101]. Moreover, higher 
levels of TUG1 correlated with disease state in both CLL 
and MM. TUG1 has been shown to be transcriptionally 
regulated by p53 in response to DNA damage [102]. 
Notably, it is involved in repressing important cell cycle 
related genes by recruiting the PRC2 complex at chromatin 
level. Higher TUG1 expression was also observed in 
bladder urothelial carcinoma samples compared to paired 
normal urothelium [103]. 
Metastasis-associated lung adenocarcinoma 
transcript 1 (MALAT1) is a putative oncogenic lncRNA 
of more than 8000 nt transcribed from chromosome 
11q13.1, and overexpressed in several solid tumors 
including lung, colorectal, bladder and laryngeal cancers 
[104-107]. MALAT1 is highly conserved in mammals, a 
finding indicative of its potentially important function(s). 
MALAT1 localizes to nuclear speckles, a sub-nuclear 
domain suggested to coordinate RNA polymerase II 
transcription, pre-mRNA splicing and mRNA export 
[108]. Indeed, a role in the regulation of alternative 
splicing and cell cycle has been proposed for this lncRNA 
[109-111]. MALAT1 has been found to be overexpressed 
in MM and to represent a putative marker to predict MM 
progression. Specifically, Cho et al. [112] found MALAT1 
expression significantly higher in MM patients at diagnosis 
compared to treated patients or healthy individuals. In 
addition, patients who experienced disease progression 
or relapse showed a significant increased expression 
of MALAT1. Of note, the expression of MALAT1 in 
newly diagnosed patients was not correlated with the 
percentage of plasma cells in the bone marrow suggesting 
that interaction between myeloma cells and bone marrow 
microenvironment may influence MALAT1 expression. 
Very recently, Ronchetti et al. [85] confirmed and 
extended this finding showing a significant overexpression 
of MALAT1 in myeloma PCs compared to normal PCs. Of 
note, the upregulation of MALAT1 appeared associated 
with molecular pathways involving cell cycle regulation, 
p53-mediated DNA damage response, and mRNA 
maturation processes. Differently from the evidence of 
MALAT1 overexpression in MM cells [85, 112], Isin et 
al. reported that circulating levels of MALAT1 transcripts 
were found to be significantly lower in patients with 
MM compared to healthy subjects [101]. However, 
these findings will require additional studies to be fully 
elucidated. Finally, it has been recently demonstrated 
that MALAT1 regulates the transcription of the nearby 
antisense protein-coding gene LTBP3 (latent TGF-β-
binding protein) in mesenchymal stem cells (MSCs) 
from MM patients [113]. LTBP3 is known to regulate the 
bioavailability of TGF-β, which plays an important role 
in the suppression of bone formation in MM bone lesions 
[114]. More specifically, MALAT1, expressed at high 
levels in the MSCs from myeloma patients, was shown to 
recruit the transcription factor SP1 on the LTBP3 promoter 
contributing to the increase of LTBP3 expression, most 
likely by stabilizing the interaction between SP1 and SP1-
consensus sequences. Notably, knockdown of MALAT1 
significantly decreased LTBP3 transcription [113].
CONCLUSIONS
An increasing number of evidences suggests 
that lncRNAs play central roles both in normal and 
malignant hematopoiesis. In this review, we summarized 
and discussed what is known about normally expressed 
and dysregulated lncRNAs during hematopoiesis with 
a particular focus on those lncRNAs found to modulate 
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crucial genes in different pathways. In the next future, 
we expect to witness an extended identification of new 
functional lncRNAs expressed during all stages of normal 
and malignant hematopoiesis. These findings will not 
only contribute to better defining the role of lncRNAs 
in blood cell development, but might have a clinical 
impact. In fact, thanks to changes in their expression 
associated with different classes of hematological 
neoplasia, lncRNAs might be useful as novel biomarkers 
for diagnosis, prognosis and prediction of response to 
therapy. Furthermore, lncRNAs might also be potential 
therapeutic targets to be modulated, and lncRNA-based 
therapies could become an important health-care strategy 
to be considered.
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